Background: Neuroblastoma is a heterogeneous disease with diverse clinical outcomes. Current risk group models require improvement as patients within the same risk group can still show variable prognosis. Recently collected genome-wide datasets provide opportunities to infer neuroblastoma subtypes in a more unified way. Within this context, data integration is critical as different molecular characteristics can contain complementary signals. To this end, we utilized the genomic datasets available for the SEQC cohort patients to develop supervised and unsupervised models that can predict disease prognosis. Results: Our supervised model trained on the SEQC cohort can accurately predict overall survival and event-free survival profiles of patients in two independent cohorts. We also performed extensive experiments to assess the prediction accuracy of high risk patients and patients without MYCN amplification. Our results from this part suggest that clinical endpoints can be predicted accurately across multiple cohorts. To explore the data in an unsupervised manner, we used an integrative clustering strategy named multi-view kernel k-means (MVKKM) that can effectively integrate multiple high-dimensional datasets with varying weights. We observed that integrating different gene expression datasets results in a better patient stratification compared to using these datasets individually. Also, our identified subgroups provide a better Cox regression model fit compared to the existing risk group definitions. Conclusion: Altogether, our results indicate that integration of multiple genomic characterizations enables the discovery of subtypes that improve over existing definitions of risk groups. Effective prediction of survival times will have a direct impact on choosing the right therapies for patients. Reviewers: This article was reviewed by Susmita Datta, Wenzhong Xiao and Ziv Shkedy.
prognosis [1] . However, patients without MYCN amplification may also have a poor outcome. Apart from MYCN amplification, a limited set of additional variables such as age at diagnosis, stage of disease etc. are used to stratify patients into distinct risk groups. Current risk group definitions are problematic as patients within the same risk group can still show variable prognosis. For instance, some low-or intermediate-risk patients still die from the disease whereas some high-risk patients show spontaneous regression. One promising direction is to utilize the recently available genomic datasets to discover complex molecular markers that can improve patient stratification. Several studies have been recently published along this line. For instance, Oberthuer et al proposed a classifier that consists of 144 genes and showed its prognostic value using two cohorts of size 77 and 440 [2, 3] . Asgharzadeh et al aimed to improve the stratification of metastatic neuroblastomas that lack MYCN gene amplification using a classifier based on 55 genes [4] . Similarly, Vermeulen et al inferred a gene set signature from 30 training samples, and evaluated this signature with a test set of 313 samples and a validation set of 236 additional tumours [5] .
Recently, several methods have been developed to integrate multiple genomic data for cancer subtype discovery [6] [7] [8] [9] . In neuroblastoma literature, however, a large majority of the previous research have focused on one type of gene expression data (e.g., microarray) to infer molecular markers. Here, we utilized the diverse data types provided by the Sequencing Quality Control Consortium (SEQC) cohort (i.e., neuroblastoma challenge in Critical Assessment of Massive Data Analysis (CAMDA) 2017) to develop statistical models that can predict clinical outcomes in neuroblastoma. Using a linear Support Vector Machine (SVM, [10] ), we were able to achieve a performance that is very close to the best reported performance in Zhang et al for the supervised learning problem [11] . We also trained this model on the whole SEQC cohort and predicted overall survival (OS) and event-free survival (EFS) variables in two independent cohorts. Our results indicate that predicting OS and EFS is more challenging for high risk (HR) patients. We observed that focusing on only high risk patients during training improves the prediction accuracy of HR patients. In the last part of the study, we employed an unsupervised learning strategy based on kernel k-means. We used MVKKM to integrate multiple data types with the aim to identify subgroups that have significantly diverse survival profiles. We observed that integrating all gene expression datasets (i.e., RNA-seq and microarray data) improves over using these datasets individually. Also, integrating these data types with learned weights is a better option than integrating them uniformly. We also confirmed that the Cox regression model that uses our identified clusters as covariates yields a better model compared to the regression model with existing high risk / low risk (LR) labels. We repeated these analyses for the subset of patients that have Array Comparative Genomic Hybridization (aCGH) data, and reached similar conclusions. Altogether, our results suggest that utilizing genomic characterizations of tumors improve over current definitions of risk groups.
Methods

Data
RNA-seq, microarray and aCGH datasets for the SEQC cohort were downloaded from CAMDA website. Chen Suo and her colleagues have identified a potential mislabeling problem between normal and tumor samples when they compared the aCGH data against the MYCN status derived from FISH experiments (personal communication). Based on this comparison, the sign of the intensity values for 32 patients were reversed. The list of these patient ids can be found in Additional file 1. We used two versions of the RNA-seq data: SEQC_NB_MAV_G_log2.txt downloaded from CAMDA website and GSE62564_SEQC_NB_RNA-Seq_log2RPM.txt downloaded from GEO website for entry GSE62564. The data for the Versteeg cohort (GSE16476 [12] ) were downloaded from R2 database (http://r2.amc.nl), and the data for the TARGET cohort were downloaded from the following link: https:// ocg.cancer.gov/programs/target/data-matrix. Note that gene-level expression measurements were used for all our experiments. We used the limma package in R to perform differential expression analysis with RNA-seq MAV data [13] . limma outputs adjusted pvalues that are corrected for multiple testing using the Benjamini-Hochberg method [14] . seaborn.clustermap function, (https://seaborn.pydata.org/generated/seaborn. clustermap.html) in Python (single linkage, Euclidean distance, standard scale = 1) was used to generate the heatmap.
Supervised learning
We used the Support Vector Classification (SVC, http:// scikit-learn.org/stable/modules/generated/sklearn.svm. SVC.html) function available in Python's scikit-learn library for training SVM models . Feature selection is performed with the sklearn.feature_selection.SelectKBest method, (http://scikit-learn.org/stable/modules/ generated/sklearn.feature_selection.SelectKBest.html) that uses ANOVA F-values to rank the features. The only parameter that needs to be tuned is the C parameter that determines the cost of misclassification. Models with lower values of C allow for more errors and learn a large margin whereas models with higher values of C aim to classify all examples correctly and learn a small margin. We considered the values {10 6 , 10 5 , 10 4 , 10 3 , 0.1, 0.5, 1, 2, 5, 10, 20, 50, 100, 1000} for the C parameter and chose the one with the best accuracy within a nested cross-validation framework. As clinical endpoints (i.e., OS, EFS) have an unbalanced distribution in neuroblastoma cohorts, we further checked whether using class-specific weights improves the performance. Namely, we set the class-weight parameter to balanced so that the C parameter of each class is multiplied with a weight value that is inversely proportional to the corresponding class frequency in the input data. Nested cross-validation was used to decide between setting this parameter to balanced or to none.
Unsupervised learning
Multi-view clustering methods aim to integrate the complementary information present in different views as this could enable the investigation of a complex system from different angles and levels. Within the cancer subtyping problem, the hypothesis is that combining different molecular characteristics of the same disease should give more comprehensive insights about the disease than considering a single characteristic type. MVKKM is an example of these approaches [15] that is closely related to unsupervised multiple kernel k-means [16] . Multiple kernel learning is concerned with using multiple kernels for the same data type whereas multi-view learning focuses on integrating different data types or views. In this approach, each view is transformed using a kernel function. Multiple kernels obtained from different views are then combined together with weights to derive the composite kernel (K):
where v is the view index, K (v) is the kernel matrix for view v, w v indicates the weight of the kernel for view v and p is an exponent to control sparsity and needs to be fixed a priori. Assuming that p >= 1, the greater the p value, the less sparse the view weights become. This formulation can be easily extended to the case where there are multiple kernels calculated from the same view. The method iterates through two steps. In the first step, the individual kernels have to be combined to derive the composite kernel as explained above. In the second step, kernel k-means is applied on the composite kernel to infer the clustering assignment.
We used the code provided by Tzortzis et al [15] with the Radial Basis Function (RBF) kernel. RBF kernel between two samples x and y can be calculated as K(x, y) = exp(−γ ||x − y|| 2 ). To avoid selecting a specific γ parameter, we used six different γ parameters (i.e. {2 −14 , 2 −15 , 2 −16 , 2 −17 , 2 −18 , 2 −19 }) for each view. Among the set of values {1.5, 2, 2.5}, 1.5 was chosen as optimal for the sparsity parameter p based on mean silhouette score [17] . Silhouette score for sample i is calculated as
where a i is the average distance of sample i to all other samples in sample i's cluster and b i is the average distance of sample i to all the samples in the closest cluster that i is not a part of. Lastly, silhouette scores of all data points are averaged to determine the mean silhouette coefficient. The number of clusters was determined by aggregating three measures: mean silhouette score, DUNN index [18] and connectivity [19] . A weighted rank aggregation method named RankAggreg [20] was used to combine the rankings obtained by these three metrics. We ran MVKKM multiple times with random initialization due to the local optima problem in k-means. The most frequent k value among the multiple runs was identified as the number of clusters.
Predictive performance of supervised and unsupervised models
We used the survival package in R to perform KaplanMeier analysis. Because more than 80% of the SEQC data is right-censored, we applied the Cox proportional hazards regression analysis with Firth's correction (hereafter named Coxphf ) using the R package [21] . To compare between different Cox models, Bayesian Information Criterion (BIC) is calculated with the formula −2loglik + mln(n) where loglik is the log likelihood of the regression model, n is the number of samples and m is the number of parameters [22] . As an additional evaluation strategy, accelerated failure time models (AFT) was used. An iterative imputation procedure [23] was applied to handle right censoring. Root mean squared error adjusted for censoring (rmse, [24] ) and Harrell's c-index [25] were used as performance metrics. Harrell's c-index calculates the frequency of concordant pairs where a pair of patients is called concordant if the patient with the higher risk prediction experiences the event before the other patient. Harrell's c-index ranges between 0 and 1 and higher values correspond to more accurate prediction models. More details of the AFT model and the evaluation procedure can be found in [26] . The reported values are average of running 10-fold cross validation ten times.
Results and discussion
Validation of the SEQC model on independent cohorts Table 1 shows statistics about the patients and the data types of the three cohorts that we worked with. We first performed supervised learning using SVM within the SEQC dataset. The mean cross-validation accuracy of the models that predict OS (i.e., occurrence of death from disease) and EFS (i.e., occurrence of progression, relapse or death) labels is close to the best accuracy reported for the same dataset [11] (for OS: our accuracy: 0.83 vs best accuracy: 0.85 and for EFS: our accuracy: 0.78 vs best accuracy: 0.78). In addition to the linear kernel, we also tried the RBF kernel for the SVM model; however, this resulted in no improvement in prediction accuracy. Besides, we tried gradient boosting and random forest models with 
Predicting outcome in Versteeg cohort
We used our model trained on the SEQC dataset to predict OS and EFS profiles of patients in an independent cohort that is called Versteeg dataset hereafter. This dataset includes the gene expression measurements and clinical data for 88 patients. Table 2 summarizes our results on the Versteeg data where we used Area Under the receiver operating characteristic curve (AUROC) and balanced accuracy as performance metrics. Several interesting observations can be derived from these results. First, when we compare the results of predicting OS and EFS labels, we observe that we predict OS more accurately than EFS in All → All and HR → HR contexts. Surprisingly, EFS prediction is more accurate when we focus only on patients with no MYCN amplification. Here we should note that some of the models listed in Table 2 use gene expression data derived from different platforms (e.g. RNA-seq or microarray). As such, we checked whether these observations still hold if we restrict the comparison to models that use gene expression data from the same platform (Additional file 4). The optimal models identified for OS and EFS prediction in All → All and HR → HR contexts use gene expression data from the same platform whereas this is not the case for MYCN_NA → MYCN_NA context. For MYCN_NA → MYCN_NA context, if we compare models that are derived from the same platform only, we still observe that EFS prediction has better performance than OS prediction. We investigated whether using only HR patients for training improves the prediction performance of OS and EFS of HR patients. Indeed, this is the case for OS prediction as balanced accuracy increases from 0.71 to 0.79. However, the same effect is not seen in predicting EFS. To confirm that the differences in accuracy between All → All and HR → HR contexts are indeed due to the different training datasets used, we repeated the comparison with models that use gene expression data from the same platform. When RNA-seq based gene expression data is used, models that are learned from only HR patients perform better than models that are learned from all patients in predicting OS of HR patients. However, we do not observe the same improvement for microarray based models. We also checked whether accounting for unbalanced class labels improves the performance. Turning on the balanced option for class weights gives a better model in terms of training set performance except for EFS prediction in All → All model. This could be due to the fact that the EFS label is less unbalanced than the OS label in the SEQC cohort. Figure 1 shows the ROC curves for predicting OS and EFS profiles. These curves reveal that we can predict OS with a high accuracy (i.e., AUROC: 0.96 and balanced accuracy: 0.89). We compared this performance with two different studies that aimed to predict OS on the same data. The first study is by Totaro et al that focused on the IL6 gene and used its expression to classify patients into two groups [27] which results in a balanced accuracy of 0.65. The second study is from Versteeg group that aimed to predict neuroblastoma outcome irrespective of MYCN amplification [28] . To this end, they identified 157 genes as downstream targets of MYCN. They also used the Versteeg cohort data itself to confirm that the expression profile of these genes correlate with MYCN mRNA levels. Using these 157 genes, they were able to predict OS in Versteeg cohort with a balanced accuracy of 0.84. Figure 2 This result indicates that our model which is trained entirely on another cohort (i.e., SEQC) performs remarkably well on predicting OS in Versteeg cohort. The first column displays the details about the training and test sets. All → All indicates that we used the whole SEQC data for training and the whole Versteeg data for testing. All → All with only HR patients corresponds to the same model as All → All; however, here the performance metrics are only calculated for HR patients. In the third row, we used only the HR patients within the SEQC data for training and similarly we tested only on HR patients within the Versteeg data. In the last row, we only consider the patients with no MYCN amplification for training and testing sets. The Type column indicates the details of the chosen model. For gene expression, microarray data and two versions of the RNA-seq data were used. As such, this entry shows the type of the gene expression data used for the best trained model. The same entry also includes the C parameter of the SVM model and the type of the class weights (balanced or uniform)
A B 
Predicting outcome in TARGET cohort
We repeated the experiments that we performed with Versteeg cohort for the TARGET cohort. (Figure 3 and Table 3 ). One important aspect of the TARGET cohort is the high fraction of HR patients. We should note that the models that we trained from SEQC cohort are different between Tables 2 and 3 as the genes common between SEQC and Versteeg cohorts are different than the genes that are common between SEQC and TARGET cohorts.
As a first observation, we see that the accuracy of predicting OS and EFS is lower compared to our results on the Versteeg cohort. This is likely due to the different composition of HR and LR patients between the SEQC and TARGET cohorts. The accuracy of predicting both OS and EFS of HR patients increases when training is performed only with HR patients (comparing rows 2 and 3 in the table). This result is likely due to the high fraction of HR patients in TARGET cohort. When we restrict the comparison to models that use the same type of gene expression data, models derived from RNA-seq data predict both OS and EFS of HR patients more accurately when the training was performed with HR patients only (Additional file 4). Unlike our results on Versteeg cohort, predicting EFS is more accurate than predicting OS in terms of balanced accuracy. The optimal models identified for OS and EFS prediction in All → All context use gene expression data from the same platform whereas this is not the case for HR → HR and MYCN_NA → MYCN_NA contexts. For these two contexts, balanced accuracy of predicting EFS is higher than that of predicting OS even when we compare models that are derived from the same platform (Additional file 4).
Comparison of the selected features across different models
We investigated the 1000 selected features across the different models that we trained. First, we compared the OS and the EFS models that we used to predict Versteeg and TARGET cohorts. The number of genes that are common between OS and EFS models is 796 for Versteeg cohort and 793 for TARGET cohort. On the other hand, the overlap between the OS models trained with all patients and those trained with HR patients is only 88 for the Versteeg cohort and 86 for TARGET cohort. We observe similar numbers for the EFS models: 51 for Versteeg cohort and 31 for TAR-GET cohort. The overlap between the OS models trained with all patients and those trained with patients with no MYCN amplification is much higher: 384 for Versteeg A B C 
Predicting outcome in SEQC cohort
The experiments were performed in the opposite direction where we trained models using the Versteeg or TAR-GET cohorts and tested on the SEQC cohort. The linear SVM model trained on the Versteeg cohort predicts OS in SEQC cohort with a balanced accuracy of 0.80 and an AUROC of 0.86. This analysis reveals that even a small number of patients (i.e., Versteeg cohort: 88 patients) is satisfactory to learn a gene signature that can predict OS in a much larger cohort (i.e., SEQC cohort: 498 patients).
Predicting EFS resulted in a similar accuracy (balanced accuracy: 0.75 and AUROC: 0.81). We repeated the same experiments where TARGET cohort is used as the training set. As expected, the predictive accuracy was lower compared to training on the Versteeg cohort (OS: bal. accuracy is 0.77 and AUROC is 0.86 and EFS: bal. accuracy is 0.69 and AUROC is 0.7). Though, we see the opposite pattern when we try to predict the outcome of HR patients using only HR patients as the training data. Namely, TARGETtrained models (OS: bal. accuracy is 0.59 and AUROC is 0.73) achieve a better predictive accuracy than Versteegtrained models (OS: bal. accuracy is 0.58 and AUROC is 0.61). This is likely related to the much larger set of HRonly training data in TARGET cohort (TARGET: 217 vs Versteeg: 36).
Unsupervised learning approaches for patient stratification
In addition to supervised learning approaches to predict OS and EFS in SEQC and other cohorts, we also investigated integrative clustering approaches to identify neuroblastoma subtypes in an unsupervised manner. To this end, MVKKM method was utilized which can cluster samples by integrating multiple data types. In MVKKM Column descriptions are same as Table 2 method, each data type is considered as a view, and multiple kernels can be used to represent each view. Because the relevance of the different views (or even the relevance of the different kernels in the same view) to the clustering task can vary, MVKKM learns a weight distribution across the kernels. This weight distribution enables the contribution of different kernels in varying degrees. Also, clustering the samples in the kernel space provides flexibility in applying non-linear feature transformations. First, we applied MVKKM to all the patients to integrate different types of gene expression data. We used six RBF kernels with different gamma parameters for each view (See Methods). Table 4 compares the clusters obtained by using different datasets: (i) RNA-seq (MAV);(ii) RNA-seq (RPM); (iii) RNA-seq data (MAV and RPM); (iv) microarray data only ;(v) RNA-seq data and the microarray data (three views). We also included results for integration of RNA-seq and microarray datasets with uniform weights rather than MVKKM-learned weights. In all cases, the number of clusters was chosen as 2 based on mean silhouette score. To compare different patient stratification models, we used Coxphf and AFT models. We included the identified clusters, age and stage information as covariates in Coxphf and AFT regression models. For Coxphf, the log-likelihood of the model is used to calculate the BIC values. For AFT models, rmse and Harrell's c-index are used for model evaluation. We observe that integrating the three types of gene expression data is better than using these datasets individually. These results also reveal that the integration of these datasets with MVKKM gives a better model than combining the kernels uniformly. When we sum the MVKKM-learned weights across the six kernels for RNA-seq (MAV), RNA-seq-(RPM) and microarray views, we obtain 0.31, 0.34 and 0.35 respectively. These weights indicate that RNA-seq-RPM and microarray datasets are more relevant for clustering neuroblastoma patients. Figure 4a shows the Kaplan-Meier analysis of obtained clusters when both RNA-seq and microarray datasets are used. The log-rank test p-value equals to 3.9e-20 confirms that the patients in the two clusters show distinct prognosis. We also investigated the fraction of LR and HR patients in our obtained clusters (Fig. 4b) . A larger proportion of cluster 1 patients are LR patients; however, HR patients still exist. The opposite trend is seen among cluster 2 patients. These distributions suggest that the current risk groups can be improved further with integrative clustering approaches. Another result that strongly supports this is the fact that our identified clusters give a much lower BIC and higher c-index compared to the existing HR / LR groups (1193 vs 1228).
We investigated the genes that are differentially expressed between the two clusters with limma method. The top 500 genes with the smallest adjusted p-values are listed in Additional file 2. Many of these genes have been previously found to be associated with neuroblastoma. The references are listed in the last column of the table. The top 50 genes are also plotted with heatmap (Additional file 3: Figure S1 ). We observe that these top 50 genes are expressed at higher levels in group 2 (High Risk).
We repeated the same analysis with a subset of patients (i.e., 145 patients) that have aCGH data. Similar to what we observed in our experiments with all patients, combining the RNA-seq and the microarray datasets gives the best model (Table 5) . Indeed, this is the only model where the discovered stratification is associated with a significant Wald-test p-value (i.e., 0.004). Interestingly, including aCGH data to this model resulted in no improvement. On the other hand, if we focus only on patients with no MYCN amplification (121 patients), including aCGH on top of gene expression datasets results in a slight improvement compared to using gene expression datasets only (BIC: 219 vs 220). For 145 patients, the MVKKMlearned weights for RNA-seq (MAV), RNA-seq (RPM) and microarray datasets were 0.30, 0.34 and 0.36 respectively. Figure 5a shows the survival plot of identified clusters. Here, we observe an intermediate risk group in addition to high risk and low risk groups. Indeed, the fraction of literature-defined LR patients increase as we go from our own high risk group to low risk group. 
Discussion
The availability of genome-wide datasets for cancer patients have increased rapidly in recent years. Methods that can effectively integrate these datasets can improve our understanding of cancer development and progression. To this end, we used supervised and unsupervised learning strategies to predict patient survival in neuroblastoma. Our supervised model can accurately predict overall survival and event-free survival profiles of neuroblastoma patients in independent cohorts. We evaluated models that are trained from RNA-seq or array-based gene expression data. Our experiments indicate that the differences in platforms of gene expression data between training and test cohorts may not be critical as RNAseq-derived models are found to perform better than microarray-derived models for many of the prediction tasks where the test cohort contains array-based gene expression data. We observed that the prognosis of HR patients is harder to predict. One strategy to improve the prediction performance of HR patients is to focus on only HR patients in the training set. To infer neuroblastoma subgroups by integrating different genomic characterizations of the patients, we utilized the MVKKM method. MVKKM has a number of advantages over other simpler clustering approaches. Namely, it uses an intermediate integration strategy that performs data integration and clustering steps concurrently.
Besides, multiple data types can be combined with different weights enabling flexible and robust data integration. Finally a major advantage of MVKKM is the use of kernel k-means that enables nonlinear transformations to the feature space. We ran MVKKM on two sets of patients: (i) all patients; (ii) subset of patients with aCGH data and compared the different models that use distinct sets of data types with Cox proportional hazards regression results. Application of Firth's correction to Cox regression was critical as we obtained completely different results without this correction (data not shown). Based on most of the evaluation criteria calculated from Cox regression and AFT models, combining all the available gene expression datasets resulted in the best model both for all the patients and for the subset of patients. For all patients, we discovered two clusters that have significantly distinct survival profiles. In parallel with the observed variability of prognosis within LR and HR patients, our identified clusters contain a mixture of LR and HR patients. For subset of patients with aCGH data, we discovered three clusters that correspond to low risk, intermediate risk and high risk groups. We observed that the proportion of literaturedefined HR patients increases as the risk level of the group increases. Interestingly, addition of aCGH data on top of the gene expression datasets resulted in no improvement for this group of patients. This could be due to the high noise level of the aCGH data. The clusters that we identified in both patient groups indicates that the current stratification of patients to high risk and low risk groups can be improved via the integrated use of genomic datasets. The performance of both supervised and unsupervised learning models can be further improved as genomic data becomes available for larger cohorts. Also, additional types of genomic data such as DNA methylation, protein expression or microRNA expression can provide opportunities to understand this complex disease from different angles and to pave the way toward improved choice of therapies. Indeed, a recent study discovered that the disruption of the let-7 microRNA family is an important mechanism in understanding cancer pathogenesis for neuroblastoma [29] .
Conclusion
Our study demonstrates that supervised learning models built from genomic datasets are suitable for clinical endpoint prediction in independent cohorts. Also, unsupervised integration of multiple genomic datasets with MVKKM reveals neuroblastoma subtypes with distinct survival profiles. Both supervised and unsupervised approaches can contribute to improved treatment stratification of neuroblastoma patients. Altogether, these results indicate that the use of multi-dimensional genomic datasets has the potential to improve current cancer risk models.
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